Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06512194
PHASE2

Investigation to Understand and Optimize Psilocybin

Sponsor: Charles Raison

View on ClinicalTrials.gov

Summary

This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.

Official title: An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

141

Start Date

2025-05-13

Completion Date

2029-05

Last Updated

2025-05-23

Healthy Volunteers

No

Conditions

Interventions

DRUG

Psilocybin

The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.

DEVICE

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.

DEVICE

Sham taVNS

Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.

Locations (1)

Vail Health Behavioral Health

Edwards, Colorado, United States